PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Develops Industry’s Only HTS Assay Kits for Screening HCV NS3/4A - Hepatitis C virus (HCV), belonging to the Flaviviridae family of positive, single stranded RNA, infects approximately 170 million people worldwide (1).
AnaSpec Develops Industry’s Only HTS Assay Kits for Screening HCV NS3/4A

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2006/07/05 - Hepatitis C virus (HCV), belonging to the Flaviviridae family of positive, single stranded RNA, infects approximately 170 million people worldwide (1)..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The HCV polyprotein consists of structural proteins (C, E1, E2 and p7), and the non-structural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) as a result of proteolytical cleavages of host signal peptidases; and metalloprotease and serine proteases, respectively.

AnaSpec has developed the industry’s only HTS assay kits for screening HCV NS3/4a. EnzoLyteTM assay kits are specifically designed for the detection and quantification of NS3/4A protease activity at subnanomolar concentrations. They can be used in 96- or 384-well microplate format. There are three assay kits to choose from depending on what wavelength is used for monitoring the cleavage of the FRET substrate. Convenient mix-and-read format and one-step procedure make EnzoLyte Assay Kits ideal for high-throughput screening.

EnzoLyteTM 490 HCV Assay Kit

Peptide substrate paired with Dabcyl (fluorophore) and Edans (quencher). Fluorescence can be continuously monitored at Ex/Em=340/490nm. Kit size: 500 assays.

EnzoLyteTM 520 HCV Assay Kit

Peptide substrate paired with 5-FAM (fluorophore) and QXLTM 520 (quencher). Fluorescence can be continuously monitored at Ex/Em=490/520 nm. Kit size: 100 assays.

EnzoLyteTM 620 HCV Assay Kit

Peptide substrate paired with HiLyte FluorTM TR (fluorophore) and QXLTM 610 (quencher). With near red emission wavelength, this FRET peptide avoids the autofluorescence interference associated with most test compounds. Fluorescence can be continuously monitored at Ex/Em=590/620nm. Kit size: 100 assays.

References:
1. CDC and Prevention. Morb. Mortal. Wkly. Rep. 47:1-39 (1998).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Develops Industry’s Only HTS Assay Kits for Screening HCV NS3/4A

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Debra Thai 
408-452-5055 marketing[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)